Counter-regulation of rejection activity against human liver grafts by donor PD-L1 and recipient PD-1 interaction.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Hepatology

• Publication date

  2016-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.jhep.2016.02.034PMID 26941095
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma

  2015cited by this paper
• Rejection triggers liver transplant tolerance: Involvement of mesenchyme‐mediated immune control mechanisms in mice

  2015cited by this paper
• Liver environment and HCV replication affect human T-cell phenotype and expression of inhibitory receptors.

  2014cited by this paper
• Protective effects of Fc-fused PD-L1 on two different animal models of colitis

  2014cited by this paper
• PD‐L1 gene polymorphisms and low serum level of PD‐L1 protein are associated to type 1 diabetes in Chile

  2014cited by this paper
• A miR-570 binding site polymorphism in the B7-H1 gene is associated with the risk of gastric adenocarcinoma

  2013cited by this paper
• Lack of association between CTLA-4 and PDCD1 polymorphisms and acute rejection in German liver transplant recipients.

  2013cited by this paper
• PD-L1 signal on liver dendritic cells is critical for Foxp3(+)CD4(+)CD25(+) Treg and liver tolerance induction in mice.

  2013cited by this paper
• Association of genetic variation in co-stimulatory molecule genes with outcome of liver transplant in Iranian patients.

  2012cited by this paper
• Inhibitory Receptors on Lymphocytes: Insights from Infections

  2012cited by this paper
• Role of the PD‐1 Pathway in the Immune Response

  2012cited by this paper
• Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

  2012cited by this paper
• Essential Role of PDL1 Expression on Nonhematopoietic Donor Cells in Acquired Tolerance to Vascularized Cardiac Allografts

  2011cited by this paper
• Identification of a Soluble Form of B7-H1 That Retains Immunosuppressive Activity and Is Associated with Aggressive Renal Cell Carcinoma

  2011cited by this paper
• Hepatic B7 homolog 1 expression is essential for controlling cold ischemia/reperfusion injury after mouse liver transplantation

  2011cited by this paper
• Immunologic basis of graft rejection and tolerance following transplantation of liver or other solid organs.

  2011cited by this paper
• Migration of allosensitizing donor myeloid dendritic cells into recipients after liver transplantation

  2010cited by this paper
• Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

  2010cited by this paper
• PD‐1/B7‐H1 Interaction Contribute to the Spontaneous Acceptance of Mouse Liver Allograft

  2010cited by this paper
• Genetic variation in microRNA networks: the implications for cancer research

  2010cited by this paper
• Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B.

  2010cited by this paper
• Lower expression levels of the programmed death 1 receptor on CD4+CD25+ T cells and correlation with the PD-1.3A genotype in patients with systemic lupus erythematosus.

  2010cited by this paper
• Antigen-presenting cell function in the tolerogenic liver environment

  2010cited by this paper
• PD-L1 has distinct functions in hematopoietic and nonhematopoietic cells in regulating T cell responses during chronic infection in mice.

  2010cited by this paper
• Chronically inflamed livers up‐regulate expression of inhibitory B7 family members

  2009cited by this paper
• Genetic, immunologic, and immunohistochemical analysis of the programmed death 1/programmed death ligand 1 pathway in human systemic lupus erythematosus.

  2009cited by this paper
• PD-1 and its ligands in tolerance and immunity.

  2008cited by this paper
• Analysis of the functional relevance of a putative regulatory SNP of PDCD1, PD1.3, associated with systemic lupus erythematosus

  2008cited by this paper
• Systemic transmigration of allosensitizing donor dendritic cells to host secondary lymphoid organs after rat liver transplantation

  2008cited by this paper
• Critical Role of Donor Tissue Expression of Programmed Death Ligand-1 in Regulating Cardiac Allograft Rejection and Vasculopathy

  2008cited by this paper
• NFATc1 Regulates PD-1 Expression upon T Cell Activation1

  2008cited by this paper
• Liver-Infiltrating Lymphocytes in Chronic Human Hepatitis C Virus Infection Display an Exhausted Phenotype with High Levels of PD-1 and Low Levels of CD127 Expression

  2006cited by this paper
• PD-L1 is induced in hepatocytes by viral infection and by interferon-α and -γ and mediates T cell apoptosis

  2006cited by this paper
• PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis.

  2006cited by this paper
• Immunoregulatory role of B7-H1 in chronicity of inflammatory responses.

  2006cited by this paper
• Polymorphisms in the T cell regulatory gene cytotoxic T lymphocyte antigen 4 influence the rate of acute rejection after liver transplantation

  2005cited by this paper
• A PD‐1 polymorphism is associated with disease progression in multiple sclerosis

  2005cited by this paper
• B7-H1 determines accumulation and deletion of intrahepatic CD8(+) T lymphocytes.

  2004cited by this paper
• Recipient CTLA‐4 +49 G/G Genotype Is Associated with Reduced Incidence of Acute Rejection After Liver Transplantation

  2003cited by this paper
• PD-1 Inhibits Antiviral Immunity at the Effector Phase in the Liver

  2003cited by this paper
• B7 Family Molecules Are Favorably Positioned at the Human Maternal-Fetal Interface1

  2003cited by this paper
• Programmed Death-1 Targeting Can Promote Allograft Survival1

  2002cited by this paper
• Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

  2002cited by this paper
• A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans

  2002cited by this paper
• Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

  2002cited by this paper
• CD28/B7 system of T cell costimulation.

  1996cited by this paper

• Expert Consensus on the Use of Immune Checkpoint Inhibitors in the Liver Transplant Setting: Guidance from the Liver Transplant Committee of the Italian Association for the Study of the Liver (AISF).

  2026cites this paper
• Immune Checkpoint Inhibitors after liver transplantation: the role of immunosuppressive management.

  2026cites this paper
• Post-Transplant Hepatocellular Carcinoma: Balancing Immunosuppression and Immune Checkpoint Inhibitors.

  2026cites this paper
• Mechanistic insights into neutrophil involvement in liver transplant ischemia-reperfusion injury and rejection

  2026cites this paper
• Extracellular Vesicles and Immune Activation in Solid Organ Transplantation: The Impact of Immunosuppression

  2025cites this paper
• TDO2 Deficiency Exacerbates the Immune Rejection Response in Rat Liver Transplantation via the Kyn-AHR Axis.

  2025cites this paper
• Aggressive surgical resection and immunotherapy for metastatic omental tumor in hepatocellular carcinoma patient after liver transplantation: a case report

  2025cites this paper
• Graft PD-L1 as a predictive marker for rejection in PD-1 inhibitor therapy for recurrent liver tumors post-transplant: A prospective pilot trial.

  2025cites this paper
• Liver Transplantation for Non-hepatocellular Carcinoma: The Role of Immune Checkpoint Inhibitors.

  2025cites this paper
• Fine-tuning tumor- and allo-immunity: advances in the use of immune checkpoint inhibitors in kidney transplant recipients

  2024cites this paper
• Immune Checkpoint Inhibitors in the Pre-Transplant Hepatocellular Carcinoma Setting: A Glimpse Beyond the Liver

  2024cites this paper
• Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis.

  2024cites this paper
• Regulatory mechanisms of PD-1/PD-L1 in cancers

  2024cites this paper
• Spatially resolved immune exhaustion within the alloreactive microenvironment predicts liver transplant rejection

  2024cites this paper
• Immune checkpoint inhibitors in liver transplantation: Current practice, challenges, and opportunities

  2024cites this paper
• Acute rejection was observed in a combination therapy of CTLA-4 and PD-1 inhibitors before liver transplantation: A case report and literature review

  2023cites this paper
• Transplant oncology – Current indications and strategies to advance the field

  2023cites this paper
• The therapeutic potential of PD-1/PD-L1 pathway on immune-related diseases: Based on the innate and adaptive immune components.

  2023cites this paper
• Current Evidence for Immune Checkpoint Inhibition in Advanced Hepatocellular Carcinoma

  2023cites this paper
• Immunotherapy and Liver Transplantation: A Narrative Review of Basic and Clinical Data

  2023cites this paper
• Extracellular Vesicles in Liver Transplantation: Current Evidence and Future Challenges

  2023cites this paper
• Case report: Predictability of clinical response and rejection risk after immune checkpoint inhibition in liver transplantation

  2023cites this paper
• Progress of PD-1/PD-L1 signaling in immune response to liver transplantation for hepatocellular carcinoma

  2023cites this paper
• Spatially resolved immune exhaustion within the alloreactive microenvironment predicts liver transplant rejection

  2023cites this paper
• Lowering maintenance immune suppression in elderly kidney transplant recipients; connecting the immunological and clinical dots

  2023cites this paper
• Optimizing the Safe Washout Period for Liver Transplantation Following Immune Checkpoint Inhibitors with Atezolizumab, Nivolumab, or Pembrolizumab.

  2023cites this paper
• Donor PD-L1 is required for organ transplant tolerance in MHC-mismatched mixed chimeras while PD-L1 and MHCII are not required for inducing chimerism.

  2023cites this paper
• Preoperative Immunotherapy in Hepatocellular Carcinoma: Current State of the Art

  2023cites this paper
• Ex vivo anchored PD‐L1 functionally prevent in vivo renal allograft rejection

  2022cites this paper
• Allograft rejection following immune checkpoint inhibitors in solid organ transplant recipients: A safety analysis from a literature review and a pharmacovigilance system

  2022cites this paper
• Immunopathological insights into villitis of unknown etiology on the basis of transplant immunology.

  2022cites this paper
• Immune Checkpoint Inhibitor Therapy Before Liver Transplantation—Case and Literature Review

  2022cites this paper
• Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review

  2021cites this paper
• Relationship of PD-1 (PDCD1) and PD-L1 (CD274) Single Nucleotide Polymorphisms with Polycystic Ovary Syndrome

  2021cites this paper
• Pretransplant use of toripalimab for hepatocellular carcinoma resulting in fatal acute hepatic necrosis in the immediate postoperative period.

  2021cites this paper
• Immunological selection and monitoring of patients undergoing pig kidney transplantation

  2021cites this paper
• PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors

  2021cites this paper
• Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells

  2021cites this paper
• Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma

  2021cites this paper
• Increased Expressions of Programmed Death Ligand 1 and Galectin 9 in Transplant Recipients Who Achieved Tolerance After Immunosuppression Withdrawal

  2021cites this paper
• Der Einsatz der immunonkologischen Therapie beim hepatozellulären Karzinom im Kontext der Lebertransplantation Eine interdisziplinäre Risiko-Nutzen-Abwägung

  2021cites this paper
• Natural killer cells in liver transplantation: Can we harness the power of the immune checkpoint to promote tolerance?

  2021cites this paper
• Der Einsatz der immunonkologischen Therapie beim hepatozellulären Karzinom im Kontext der Lebertransplantation Eine interdisziplinäre Risiko-Nutzen-Abwägung The use of immuno-oncologic therapy in hepatocellular carcinoma in the context of liver transplantation. An interdisciplinary benefit/risk asse

  2021cites this paper
• Correlations of PD-1/PD-L1 Gene Polymorphisms with Susceptibility and Prognosis in Non-Hodgkinʼs Lymphoma among Iranian Population

  2020cites this paper
• Extracellular vesicles as mediators of alloimmunity and their therapeutic potential in liver transplantation

  2020cites this paper
• Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?

  2020cites this paper
• Graft Programmed Death Ligand 1 Expression as a Marker for Transplant Rejection Following Anti–Programmed Death 1 Immunotherapy for Recurrent Liver Tumors

  2020influential citation
• Immune checkpoint inhibitor therapy in solid organ transplant recipients: A patient-centered systematic review.

  2020cites this paper
• Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups

  2020cites this paper
• Impact of donor extracellular vesicle release on recipient cell “cross‐dressing” following clinical liver and kidney transplantation

  2020cites this paper
• Considerations for immunotherapy in patients with cancer and comorbid immune dysfunction

  2020cites this paper
• Immune Checkpoint Inhibitors in Transplantation-A Case Series and Comprehensive Review of Current Knowledge.

  2020cites this paper
• Immune checkpoint inhibitors in special populations. A focus on advanced lung cancer patients.

  2020cites this paper
• Porcine genome engineering for xenotransplantation.

  2020cites this paper
• Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: A systematic review

  2020cites this paper
• Programmed death-ligand 1 single nucleotide polymorphism affects breast cancer chemosensitivity and adverse events in the neoadjuvant setting

  2020cites this paper
• Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex-vivo targeting immune checkpoint molecules.

  2019cites this paper
• Toxicities in Immune Checkpoint Inhibitors

  2019cites this paper
• HBV and HIV/HBV Infected Patients Have Distinct Immune Exhaustion and Apoptotic Serum Biomarker Profiles

  2019cites this paper
• Clinical impact of low serum free T4 in patients with non-small cell lung cancer treated with nivolumab

  2019cites this paper
• Title Clinical Impact of Single Nucleotide Polymorphism in PD-L 1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients

  2019cites this paper
• Harnessing immunotherapy for liver recipients with hepatocellular carcinoma: a review from a transplant oncology perspective

  2019cites this paper
• Potential Beneficial Effects of Cytomegalovirus Infection after Transplantation

  2018cites this paper
• Pigs expressing the human inhibitory ligand PD‐L1 (CD 274) provide a new source of xenogeneic cells and tissues with low immunogenic properties

  2018cites this paper
• Graft‐infiltrating PD‐L1hi cross‐dressed dendritic cells regulate antidonor T cell responses in mouse liver transplant tolerance

  2018cites this paper
• Association of PD-1 and PD-L1 Genetic Polymorphyisms with Type 1 Diabetes Susceptibility

  2018cites this paper
• Immune-checkpoint inhibitors to treat cancers in specific immunocompromised populations: a critical review

  2018cites this paper
• Blockade of LAG3 enhances responses of tumor-infiltrating T cells in mismatch repair-proficient liver metastases of colorectal cancer

  2018cites this paper
• "No pain, No gain" still true with immunotherapy: When the finger shows the moon, look at the moon!

  2018cites this paper
• Co-Signaling Molecules in Maternal-Fetal Immunity.

  2017cites this paper
• Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients

  2017cites this paper
• Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes

  2017cites this paper
• Immune checkpoint inhibitors in challenging populations

  2017cites this paper
• Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.

  2017cites this paper
• PD-L1, Galectin-9 and CD8+ tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma

  2017cites this paper
• Mechanisms of liver-induced tolerance

  2016cites this paper
• The CD8 T-cell response during tolerance induction in liver transplantation

  2016cites this paper
• Mechanisms and Strategies for Tolerance in Liver Transplantation

  2016cites this paper